Recombinant Human IL‑10 R beta Fc Chimera (Catalog # 874-RB)
2.5 µg/106 cells
Human whole blood monocytes
Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
Measured by its ability to neutralize IL‑10 R beta -mediated IL‑10 response in LPS-activated human peripheral blood mononuclear cells (PBMC). Ralph, P. et al. (1991) J. Immunology 148:808. The Neutralization Dose (ND50) is typically 2-6 µg/mL in the presence of 0.25 ng/mL Recombinant Human IL‑10 and 0.25 ng/mL LPS.
Please Note: Optimal dilutions should be determined by each laboratory for each application.
are available in the Technical Information section on our website.
IL‑10 Inhibition of IL‑1 beta secretion and Neutralization by Human IL‑10 R beta Antibody.
Recombinant Human IL‑10 (Catalog # 217-IL) inhibits IL‑1 beta secretion in LPS-activated human peripheral blood mononuclear cells (PBMC) in a dose-dependent manner (orange line), as measured by the Human IL‑1 beta /IL‑1F2 Quantikine ELISA Kit (Catalog # DLB50). IL‑1 beta secretion inhibited by Recombinant Human IL‑10 (0.25 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IL‑10 R beta Antigen Affinity-purified Polyclonal Antibody (Catalog # AF874). The ND50 is typically 2-6 µg/mL in the presence of LPS (0.25 ng/mL).
Preparation and Storage
Reconstitute at 0.2 mg/mL in sterile PBS.
Reconstitution Buffer Available
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IL-10 R beta
IL-10, also known as IL-10 R2, mediates its biological activities via binding to a heteromeric receptor complex consisting of two distinct type II cytokine receptor subunits, the ligand binding IL-10 R alpha and the IL-10 R beta which does not bind IL-10 by itself but is required for signal transduction. The cDNA for human IL-10 R beta encodes a 325 amino acid (aa) residue type I transmembrane precursor protein with a 20 aa signal sequence, a 200 aa extracellular region, a 29 aa transmembrane segment, and a short 76 aa cytoplasmic domain. Within the extracellular region, there are two 100 aa subdomains that resemble the constant region of immunoglobulins. This structural motif is responsible for the alternative designation of IL-10 R beta as CRF2-4 (the 4th member of the cytokine receptor family class II/2). Human and mouse IL-10 R beta share approximately 69% aa sequence identity. Binding of the non-covalent IL-10 dimer to two IL-10 R alpha chains recruits two IL‑10 R beta chains resulting in the activation and phosphorylation of the signaling cascade involving JAK1, TYK2, and STAT3. IL-10 R beta is expressed ubiquitously. IL‑10 R beta is also a component of the IL-22 receptor complex consisting of the IL-10 R beta chain and IL-22 R, another type II cytokine receptor family member.
Donnelly, R.P. et al. (2004) J. Leukoc. Biol. 76:314.
Donnelly, R.P. et al. (1999) J. Interferon Cytokine Res. 19:563.
Kotenko, S.V. et al. (2000) J. Biol. Chem. 276:2725.
R&D Systems personnel manually curate a database that contains references using R&D Systems products.
The data collected includes not only links to publications in PubMed,
but also provides information about sample types, species, and experimental conditions.
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.